Abstract
Treatment of recurrent or unresectable cutaneous and subcutaneaous tumors continues to be a major therapeutic challenge. Electrochemotherapy (ECT) is a palliative treatment of cutaneous and subcutaneous tumor nodules for which standard treatments (e.g. radiotherapy, chemotherapy, and surgery) have failed or proved to be insufficient. ECT combines the electropulsation of tumor cells (by local application of electric pulses) and the administration of antineoplastic drugs such as cisplatin or bleomycin (either intravenous or intratumoral). The permeability of the cancer cells to these poorly permeant anti-tumor drugs is transiently increased up to a hundred-fold. ECT is thus an efficient loco-regional therapy for palliative treatment of unresectable recurrent tumor nodules with overall objective response rates of approximatively 80-90% and has satisfactory cosmetic results. The next challenge for ECT is the treatment of deep-seated tumors and metastases. The joint therapy of ECT and electrotransfer of immune-stimulating genes or electro-photodynamic therapy could be a promising strategy for cancer eradication.
Keywords: Electrochemotherapy, Electropermeabilization, Cisplatin, Bleomycin, clinical trials, subcutaneaous tumors, electrotransfer, immune-stimulating genes, electro-photodynamic therapy, cancer
Current Pharmaceutical Design
Title:Electrochemotherapy: Progress and Prospects
Volume: 18 Issue: 23
Author(s): Jean-Michel Escoffre and Marie-Pierre Rols
Affiliation:
Keywords: Electrochemotherapy, Electropermeabilization, Cisplatin, Bleomycin, clinical trials, subcutaneaous tumors, electrotransfer, immune-stimulating genes, electro-photodynamic therapy, cancer
Abstract: Treatment of recurrent or unresectable cutaneous and subcutaneaous tumors continues to be a major therapeutic challenge. Electrochemotherapy (ECT) is a palliative treatment of cutaneous and subcutaneous tumor nodules for which standard treatments (e.g. radiotherapy, chemotherapy, and surgery) have failed or proved to be insufficient. ECT combines the electropulsation of tumor cells (by local application of electric pulses) and the administration of antineoplastic drugs such as cisplatin or bleomycin (either intravenous or intratumoral). The permeability of the cancer cells to these poorly permeant anti-tumor drugs is transiently increased up to a hundred-fold. ECT is thus an efficient loco-regional therapy for palliative treatment of unresectable recurrent tumor nodules with overall objective response rates of approximatively 80-90% and has satisfactory cosmetic results. The next challenge for ECT is the treatment of deep-seated tumors and metastases. The joint therapy of ECT and electrotransfer of immune-stimulating genes or electro-photodynamic therapy could be a promising strategy for cancer eradication.
Export Options
About this article
Cite this article as:
Escoffre Jean-Michel and Rols Marie-Pierre, Electrochemotherapy: Progress and Prospects, Current Pharmaceutical Design 2012; 18 (23) . https://dx.doi.org/10.2174/138161212801227087
DOI https://dx.doi.org/10.2174/138161212801227087 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aldose Reductase, Still a Compelling Target for Diabetic Neuropathy
Current Drug Targets CYLD-Mediated Signaling and Diseases
Current Drug Targets Decorin Biology, Expression, Function and Therapy in the Cornea
Current Molecular Medicine Stathmin, Interacting with Nf-κB, Promotes Tumor Growth and Predicts Poor Prognosis of Pancreatic Cancer
Current Molecular Medicine Signs and Related Mechanisms of Ethanol Hepatotoxicity
Current Drug Abuse Reviews NMR in Metabolic Profiles of Neural Stem/Progenitor Cells: Current Status and Relevant Problems
Current Medical Imaging Stemness or Not Stemness? Current Status and Perspectives of Adult Retinal Stem Cells
Current Stem Cell Research & Therapy Advances in Helper-Dependent Adenoviral Vector Research
Current Gene Therapy Virulence Factors of Candida albicans Isolates from the Oral Cavities of HIV-1-Positive Patients
Current HIV Research Synergistic Effects of Linderanolide B Combined with Arbutin, PTU or Kojic Acid on Tyrosinase Inhibition
Current Pharmaceutical Biotechnology BCR-ABL Inhibitors in Chronic Myeloid Leukemia: Process Chemistry and Biochemical Profile
Current Medicinal Chemistry Cancer Stem Cells in Solid and Liquid Tissues of Breast Cancer Patients: Characterization and Therapeutic Perspectives
Current Cancer Drug Targets Hypericin Lights Up the Way for the Potential Treatment of Nasopharyngeal Cancer by Photodynamic Therapy
Current Clinical Pharmacology Transforming Growth Factor β Signaling Perturbation in the Loeys-Dietz Syndrome
Current Medicinal Chemistry Living Heart Valve and Small-Diameter Artery Substitutes - An Emerging Field for Intellectual Property Development
Recent Patents on Biotechnology Prodigiosins as Anti Cancer Agents: Living Upto Their Name
Current Pharmaceutical Design Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition
Current Genomics Small Molecules and Future Regenerative Medicine
Current Topics in Medicinal Chemistry Desferrioxamine as Immunomodulatory Agent During Microorganism Infection
Current Pharmaceutical Design Innate Immune Surveillance in the Central Nervous System Following Legionella pneumophila Infection
CNS & Neurological Disorders - Drug Targets